Commonwealth Equity Services LLC Has $49.95 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Commonwealth Equity Services LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,202,754 shares of the biopharmaceutical company’s stock after purchasing an additional 79,413 shares during the quarter. Commonwealth Equity Services LLC owned 0.06% of Bristol-Myers Squibb worth $49,950,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. ESL Trust Services LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter valued at about $27,000. Northwest Financial Advisors acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $34,000. Fairman Group LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $42,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $47,000. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Cantor Fitzgerald restated a “neutral” rating and set a $45.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Jefferies Financial Group upped their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday. TD Cowen boosted their price target on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $54.67.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $49.95 on Friday. The company’s 50 day simple moving average is $45.17 and its two-hundred day simple moving average is $46.57. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.03. The stock has a market capitalization of $101.27 billion, a PE ratio of -16.11, a P/E/G ratio of 12.92 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. During the same quarter last year, the firm posted $1.75 EPS. The company’s revenue was up 8.7% compared to the same quarter last year. Analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were given a dividend of $0.60 per share. The ex-dividend date was Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 4.80%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.